Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　― Insights From GARFIELD-AF ―

Abstract

Western countries. 5 AF-related stroke is more likely to be fatal or lead to long-term disability than stroke in people without this arrhythmia. 6 Stroke prevention is therefore a principal goal in the management of patients with AF who are at high risk of stroke. 7 The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective non-interventional study of stroke prevention in patients with newly diagnosed AF that is being conducted in 35 countries. 8 In Japan, patients were enrolled between 2010 and 2016 from 301 representative care settings and are A trial fibrillation (AF) is the most common arrhythmia worldwide. 1 The estimated prevalence in the Japanese general population is 1.6% 2 in patients >40 years and 2-3% in people >80 years of age. 2 As life expectancy increases, the number of AF patients in Japan is anticipated to exceed 1 million by 2050. 3 Although the prevalence of AF in Asian countries is approximately half that in countries with predominantly Caucasian populations, nevertheless patients in Japan with AF have a higher overall disease burden compared with other countries because of its proportionally greater elderly population. 3,4 In Japan, for example, more patients with AF ≥60 years of age present

Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy

“…In addition, OAC-related major bleeding rates may generally be lower among Japanese patients than in patients from other countries, as exemplified by the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GAR-FIELD-AF) ongoing multi-national observational study of stroke prevention in patients with newly diagnosed NVAF [24]. In this study, the major bleeding event rate in Japan was 0.32 (95% CI 0.19-0.53) per 100 patient-years versus 0.91 (0.82-1.00) per 100 patient-years in other countries [24]. Major bleeding incidence rates in one Japanese study were 2.2 per 100 patientyears (patients aged C 75 years) and 1.4 per 100 patient-years (patients aged \ 75 years) among 9578 NVAF patients receiving rivaroxaban [25].…”

Real-World Antithrombotic Therapy in Atrial Fibrillation Patients with a History of Percutaneous Coronary Intervention

“…As shown in Figure 2 in this study, the proportion of DOAC as OAC increased year on year after the launch of DOAC, in line with the results of Fushimi-AF study 1) and GARFIELD AF registry. 23) The safety profile of DOAC [24][25][26][27] may have contributed to the increase in the proportion of OAC prescription for patients AF receiving PCI. However, in terms of the efficacy and safety of DOAC monotherapy for such patients in the chronic phase of the disease remain unknown.…”

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction

“…Primary outcomes were defined as IS/SE, major bleeding, and death from any cause 19 . The major bleeding was defined according to principle or secondary diagnosis of hospitalization and emergency visit and any blood transfusion order, which included admission for any bleeding, required blood transfusion >2 U, and life‐threatening bleeding or vital organ haemorrhage, which included intracerebral haemorrhage.…”

“…Primary outcomes were defined as IS/SE, major bleeding, and death from any cause. 19 The major bleeding was defined according to principle or secondary diagnosis of hospitalization and emergency visit and any blood transfusion order, which included admission for any bleeding, required blood transfusion >2 U, and life-threatening bleeding or vital organ haemorrhage, which included intracerebral haemorrhage. The follow-up period was defined as the period from the index date until the occurrence of study outcome, date of up to 5 years of follow-up, or the end date of the study period (31 December 2018), whichever came first.…”